Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up

• DOI: 10.1016/j.ejso.2020.02.011
• Publication Date: 2020-03-12T18:08:30Z
• Authors: S. Kusamura; V. Kepenekian; L. Villeneuve; R.J. Lurvink; K. Govaerts; I.H.J.T. De Hingh; B.J. Moran; K. Van der Speeten; M. Deraco; O. Glehen; Pedro Barrios-San...; Joel M. Baumgartner; Almog Ben-Yaacov; Rosella Bertulli; Peter Cashin; Tom Cecil; Sanjeev Dayal; Michele De Simone; Jason M. Foster; Diane Goere; Kuno Lehmann; Yan Li; Brian W. Loggie; Faheez Mohamed; David L. Morris; Aviram Nissan; Pompiliu Piso; Marc Pocard; Beate Rau; Marc A. Reymond; Lucas Sideris; John D. Spiliotis; Paul H. Sugarbaker; Victor J. Verwaal; Malcom S. Wilson; Yutaka Yonemura; Yang Yu
• Keywords: Diagnostic Imaging; Mesothelioma; 03 medical and health sciences; 0302 clinical medicine; Delphi Technique; Humans; Cytoreduction Surgical Procedures; Hyperthermic Intraperitoneal Chemotherapy; Peritoneal Neoplasms; 3. Good health

Peritoneal mesothelioma (PM) is a rare and aggressive primary peritoneal malignancy characterized by widespread multiple metastatic tumour nodules originating from the peritoneum. The conventional classification distinguishes diffuse malignant peritoneal mesothelioma (DMPM) and border-line forms: multicystic peritoneal mesothelioma (MCPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM). Despite the novel achievements in the management of PM, there is difficulty in conducting randomized trials due to its rarity and aggressive biology in many cases. As there is, a necessity to standardize diagnosis and management of PM, the Peritoneal Surface Oncology Group International (PSOGI) commissioned a steering committee to elaborate clinical guidelines.